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Summary
FTY720 is an immunomodulator with demonstrated ef-
ficacy in a phase II trial of relapsing multiple sclerosis.
FTY720-phosphate, the active metabolite generated
upon phosphorylation in vivo, acts as a potent agonist
on four of the five known sphingosine-1-phosphate
(S1P1) receptors. AUY954, an aminocarboxylate ana-
log of FTY720, is a low nanomolar, monoselective ag-
onist of the S1P1 receptor. Due to its selectivity and
pharmacokinetic profile, AUY954 is an excellent phar-
macological probe of S1P1-dependent phenomena.
Oral administration of AUY954 induces a profound
and reversible reduction of circulating lymphocytes
and, incombinationwithRAD001 (Certican/Everolimus,
an mTOR inhibitor), is capable of prolonging the sur-
vival of cardiac allografts in a stringent rat transplanta-
tion model. This demonstrates that a selective agonist
of the S1P1 receptor is sufficient to achieve efficacy in
an animal model of transplantation.
Introduction
Sphingosine-1-phosphate (S1P) is an evolutionarily
conserved bioactive sphingolipid. S1P is generated as
a metabolite of ceramide and secreted into serum
by mast cells, platelets, and monocytes. It has been
implicated as a second messenger in cellular prolifera-
tion and survival and in protection against ceramide-
mediated apoptosis. In addition, S1P regulates diverse
physiological processes such as cell migration, angio-
genesis, vascular maturation [1, 2], and immunity [3–6]
by serving as a ligand to cell-surface G-protein-coupled
S1P receptors [7, 8].
*Correspondence: nathanael_gray@dfci.harvard.eduFTY720 is a synthetic analog of the natural product
myriocin that shares structural homology with the
endogenous sphingolipid sphingosine. As a novel im-
munomodulatory agent, FTY720 exhibited promising
activity in animal models of organ transplantation and
autoimmunity [9, 10]. In combination with cyclosporin
(CsA), FTY720 has proven to be efficacious in preventing
kidney rejection in humans [11] and entered phase III
clinical trials for transplant rejection [12]. However, fur-
ther development for this indication was discontinued
since FTY720 did not provide benefits over standard of
care. FTY720 is now being developed for the treatment
of multiple sclerosis and is entering a phase III trial after
having reduced clinical relapse in a phase II study by
greater than 50% relative to placebo in 6 months [13].
Upon phosphorylation in vivo primarily by sphingo-
sine kinase 2 (SK2) [14], FTY720 acquires the ability to
mimic sphingosine-1-phosphate (S1P) and acts as
a potent agonist at four of the five known sphingosine-
1-phosphate receptors, namely S1P1, S1P3, S1P4, and
S1P5 (Figure 1) [3, 15]. It has been convincingly demon-
strated that FTY720-phosphate-mediated S1P receptor
agonism causes inhibition of lymphocyte egress from
thymus and lymph nodes, which is—at least in part—
responsible for the immunomodulatory activity of
FTY720 [16–18]. Recent reports demonstrate the re-
quirement of the S1P1 receptor for the desired pharma-
codynamic response in vivo [19]. In addition, a transient
and asymptomatic bradycardia has been reported as
the primary clinical adverse effect of FTY720 [20], and
S1P3 has been demonstrated to regulate heart rate in ro-
dents [21], apparently by activating G-protein-coupled
inward-rectifying potassium (GIRK) channels in atrial
myocytes [22]. We therefore sought to determine the
minimal receptor profile required to provide full protec-
tion of organ transplants in vivo. To accomplish this,
we prepared a series of novel amino carboxylate ana-
logs and profiled their selectivity against the S1P recep-
tors by using functional GTPgS binding assays. Here, we
demonstrate that a compound with monoselectivity for
the sphingosine-1-phosphate receptor-1 (S1P1) is capa-
ble of potently reducing circulating lymphocytes and
protecting rat heart allografts in vivo in combination
therapy with a subtherapeutic dose of RAD001.
Results and Discussion
Design and Synthesis of AUY954: A S1P1
Monoselective Agonist
FTY720 acts as a prodrug and is converted to an active
aminophosphate metabolite through sphingosine-ki-
nase-2-mediated phosphorylation in vivo. Due to poten-
tial complexities associated with prodrugs such as spe-
cies differences between the kinase and phosphatase
responsible for controlling drug levels, we and others
[23] sought to prepare non-prodrug aminocarboxylate
bioisoteres. Recently, a series of orally bioavailable tri-
cyclic carboxylate analogs have also been reported as
S1P1 selective agonists [23]. These and earlier com-
pound series developed by the Merck group [24]
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1228Figure 1. Chemical Structures and Func-
tional Activity of FTY720, FTY720-Phos-
phate, and AUY954 on S1P Receptors
(A) Chemical structures of FTY720, FTY720-
phosphate, and AUY954.
(B) EC50 in nanomolar (mean 6 SEM) for the
compounds against S1PRs in a g-GTPS-
binding assay.demonstrated that the aminophosphate ‘‘head group’’
can be functionally mimicked by an amino carboxylate
and is sufficient to achieve potent agonist activity. The
discovery of the S1P1 selective agonist SEW02871 [21]
demonstrated that modifications made to the parts of
the inhibitor that interact with the hydrophobic channel
of the S1P receptor allow S1P1 subtype selectivity to
be achieved. SEW02871 achieves significant agonist
activity (EC50 = 14 6 8 nM) despite being incapable of
forming ionic interactions with the receptor [25]. It is
postulated that the trifluoromethyl groups contributes
significantly to the binding affinity. AUY954 (Figure 1)
was inspired by combining structural features derived
from screening leads related to SEW02871 that were ob-
tained from a high-throughput screen of the S1P1 recep-
tor. Although the trifluoromethyl biphenyl substitutent of
AUY954 was identified by a systematic structure activity
relationship (SAR) analysis, it can be retrospectively
viewed as an isosteric replacement of the trifluoro-
methyl-thiophene-phenyl fragment of SEW02871. Thepotential for molecular mimicry between AUY954 and
SEW02871 [25] can be visualized when these com-
pounds are docked to a homology model of S1P1 (Fig-
ure 2). Interestingly, an energetically preferred binding
mode has the two compounds closely overlapped, es-
pecially in the trifluoromethyl region. AUY954 was finally
obtained after installing different amino carboxylate
‘‘head groups’’ to a diverse assortment of benzo-fused
heterocycles that possessed the trifluoromethyl-biphe-
nyl pharmacophore (unpublished data) [26]. AUY954
exhibited monoselectivity for S1P1 over all other S1P re-
ceptors (S1P2–5) as assessed by GTPgS-binding assays
(see section below). The synthesis of AUY954 was com-
pleted in seven steps (Figure 3). Thus, the boronic acid 2
was obtained from benzothiophene compound 1 upon
treatment of lithium diisopropylamide and trimethyl bo-
rate. Its coupling counterpart (5) was prepared in two
steps starting with Suzuki coupling of commercially
available 3-trifluoromethyl-4-bromoaniline (3) with phe-
nylboronic acid followed by a diazotization-brominationFigure 2. Comparative Binding Mode of AUY954 and SEW02871 Bound to Homology Model of S1P1
AUY954 and SEW02871 are shown in cyan and brown, respectively (heteroatoms are colored red for oxygen, blue for nitrogen, green for
fluorine, and yellow for sulfur), and S1P1 in red ribbons. Possible ionic interactions are shown as dotted lines to Glu121 to amine and
Arg120 to acid of AUY954.
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1229Figure 3. Synthetic Scheme for AUY954
Reagents: (a) i. LDA, B(OMe)3, THF,278
C to
RT, overnight; ii. HCl, 88%; (b) PhB(OH)2,
Pd(OAc)2, phosphine ligand, KF, THF, reflux,
overnight, 70%; (c) CuBr2, t-BuONO, CH3CN,
0C to RT, overnight, 65%; (d) Pd(PPh3)4,
Na2CO3, PhCH3-EtOH-H2O, 80
C, 6 hr,
74%; (e) NBS, AIBN, CCl4, reflux, 10 hr; (f)
NaH, b-alanine t-butyl ester, DMF, RT, over-
night, 62% for two steps; (g) TFA, CH2Cl2,
66%.reaction. Bromide 7 was obtained by a Suzuki coupling
reaction between 2 and 5 followed by bromination with
N-bromosuccinimide. AUY954 (9) was obtained by ami-
nation with b-alanine t-butyl ester, followed by removal
of the t-butyl protecting group with trifluoroacetic acid.
AUY954 Is Selective for S1P1
AUY954 was tested for its ability to stimulate the binding
of GTPgS to S1P1, S1P2, S1P3, S1P4, and S1P5 receptor
G-protein complexes expressed in recombinant human
CHO cell membranes (Figure 1). The EC50 of AUY954 for
S1P1 receptor activation was 1.2 nM, which is compara-
ble to the measured and reported [15] EC50 for FTY720-
phosphate. AUY954 exhibited at least 280-fold greater
selectivity against the other four receptor subtypes.
In addition, AUY954 also showed comparable activityon the murine S1P1 receptor (Figure 1). AUY954 was
also tested at a concentration of 10 uM for selectivity
against a diverse panel of receptors and ion channels,
and no appreciable binding affinity (IC50 > 1 uM) was
observed.
AUY954 Induces ERK and AKT Phosphorylation
In order to ascertain whether AUY954 induces activation
of kinase cascades downstream of receptor activation
as has been reported for S1P1 and SEW02871, we mea-
sured the levels of phosphorylation of Erk and Akt fol-
lowing treatment of S1P1 expressing CHO cells with
AUY954. AUY954 increased Erk (tyrosine residue 204)
and Akt phosphorylation (serine residue 473) levels
with an EC50 of approximately 0.1 and 1 nM, respectively
(Figure 4). This EC50 is in close agreement with the EC50Figure 4. AUY954 Induces Activation of Erk
and Akt Kinases in CHO Expressing S1P1
(A) Western blot analysis of phospho-Akt, to-
tal Akt, phospho-Erk, and total Erk, following
5 min stimulation of CHO-S1P1 cells with
varying concentrations (3-fold dilution series
starting at 100 nM) of AUY954 or S1P.
(B) EC50 (mean 6 SEM) of S1P and AUY954
for phospho-Akt and phospho-Erk as calcu-
lated from western blot analysis.
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1230Figure 5. AUY954 Induced Potent and Reversible Peripheral Lymphocyte Depletion in Lewis Rats
(A) AUY954 was administered orally at 3, 1, 0.3, and 0.1 mg/kg to Lewis rats and dose-dependently depleted peripheral lymphocytes. Results
are expressed as peripheral lymphocyte counts (PLC) as compared to baseline. The mean 6 SEM of five animals is shown.
(B) Profile of peripheral lymphocyte counts related to plasma concentrations of AUY954 after oral administration at 3 mg/kg.
(C) Comparison of AUC and trough level (mean 6 SEM) of AUY954 and RAD001 for different dosing groups.for S1P1 receptor activation measured by GTPgS bind-
ing. No activation of Erk or Akt was observed when
wild-type CHO cells were incubated with S1P and
AUY954 (data not shown).
AUY954 Causes a Profound, Reversible, and Dose-
Dependent Reduction of Circulating Lymphocytes
Sustained by Blood Agonist Levels
Oral administration of AUY954 induces a rapid, potent,
and dose-dependent decrease in the number of periph-
eral lymphocytes in Lewis rats (Figure 5). The effective
dose required to achieve a 50% reduction (ED50) in cir-
culating lymphocytes is 0.7 mg/kg, which represents
the time at which the nadir of circulating lymphocyte re-
duction is reached. Peripheral lymphocyte counts return
to untreated levels 48 hr after compound treatment. The
pharmacokinetic profile of AUY954 in Lewis rats and
cynomologus monkeys further reveals good oral bio-
availability (33% and 74%, respectively) and short elim-
ination half lives (t1/2 of 5.0 and 11.6 hr, respectively)
compared to FTY720 and its phosphate (t1/2 of 21–28
hr and 33–52 hr, respectively). In order to investigate
pharmacodynamics, drug levels and decrease of circu-
lating lymphocytes were simultaneously assessed in
Lewis rats following an oral dose of 3 mg/kg of
AUY954. There is an inverse relationship between the
number of circulating blood lymphocytes and blood
concentration of AUY954 over a 72 hr time interval fol-
lowing oral administration (Figure 5B). The rapid onset
and maintenance of circulating lymphocyte reduction
was associated with a systemic exposure of agonist in
the range of 100–300 nM, with a recovery of peripheral
lymphocytes concomitant with the decline of bloodlevels. Therefore, this pharmacodynamic effect of
AUY954 appeared to be a response to S1P1 agonism.
AUY954 Treatment, in Combination with
Subtherapeutic Dose of RAD001, Significantly
Prolongs Graft Survival of Heterotopic
Cardiac Transplants
Sequestration of circulating mature lymphocytes into
secondary lymphoid organs is thought to be the main
mechanism underlying the immunomodulatory action
of FTY720. In light of the high efficacy of FTY720 in the
prevention of transplant rejection in several animal
models and the comparable potency of AUY954 in in-
ducing peripheral lymphocyte depletion in vivo, we con-
ducted a study to investigate the ability of this S1P1 se-
lective agonist to prolong allograft survival. As previous
studies have demonstrated that FTY720 synergizes ef-
fectively with inhibitors of T cell activation and prolifera-
tion [16, 27, 28], we examined whether treatment with
AUY954 in combination with RAD001 would extend rat
heart allografts by using the stringent DA to Lewis strain
combination. A subtherapeutic dose of RAD001 of
0.3 mg/kg/d was coadministered with AUY954 at 1, 3,
and 10 mg/kg/day for 26 days with 3 days of pretreat-
ment before transplantation (Table 1). In placebo-
treated rats, all cardiac allografts were rejected within
10 days, with a median graft survival time (MST) of 6
days, while a MST of 7 days was obtained by using
RAD001 at 0.3 mg/kg/d alone. In contrast, at an oral
dose of 3 and 10 mg/kg/day of AUY954 in combination
with RAD001, all grafts reached the termination point
of 26 days. However, signs of cellular infiltration were
evident in all AUY954/RAD001 combination groups.
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1231Table 1. Efficacy of AUY954 in DA-to-Lewis Rat Heart Transplantation in Combination with RAD001
AUY954/Dose
(mg/kg/day)
RAD001 Dose
(mg/kg/day)
Individual Survival
(days)
Survival MST
(days)
Cmax
(nM)
Mean Cellular
Rejection Score
Lymphocyte Count
(units/ml)
0 0 6, 6, 6, 6, 6, 7, 10 6 — 4 6 0 11,173 6 716
0 0.3 7, 7, 7, 7, 11, 19 7 — 3.7 6 0.2 8,670 6 230
1 0.3 9, 15, 17, >28, >28 17 240 6 101 3.6 6 0.2 4,810 6 330
3 0.3 >26, >26, >26, >26, >26 >26 576 6 40 2.6 6 0.2 1,860 6 190
10 0.3 >26, >26, >26, >26, >26 >26 2,295 6 171 2.2 6 0.2 1,460 6 100Histology of heart allografts at the termination point of
9–26 days showed moderate to severe acute cellular
rejection dependent on the doses of AUY954. These
results were comparable to FTY720 in the same model
(data not shown).
Measurement of the number of peripheral blood lym-
phocytes 8 hours after the last dosing reveals reduction
percentages of 43.0, 16.6, and 13.1 for 1, 3, and 10 mg/
kg/day dosing groups, respectively. Analysis of the
blood levels of AUY954 demonstrates a linear dose-de-
pendent exposure as assessed by Cmax, Clast, and AUC
(Figure 5). The blood exposure of RAD001 remained un-
altered regardless of the AUY954 dose, which suggests
that AUY954 does not alter the metabolism of RAD001.
In our rat transplantation model, which strongly in-
duces acute rejection within 6 days, AUY954 in synergy
with RAD001 effectively prolonged the survival of car-
diac allografts. These data prove that graft protection
can be achieved by specifically targeting the S1P1
GPCR receptor in vivo and further define an essential re-
quirement for this specific receptor in mediating useful
immune suppression in transplantation.
Significance
The functional roles of the S1P receptor subtypes in
different tissues remains an area of active research.
Growing evidence, especially from the use of the
promising immunomodulatory drug FTY720, supports
a role for S1P receptors in regulating lymphocyte recir-
culation and trafficking. Recent reports using selec-
tive agonists implicate S1P1 as the crucial target for
agonist-induced peripheral lymphocyte reduction,
while they suggest a role for S1P3 in the regulation of
heart rate in rodents [21, 29]. Studies using hematopoi-
etic cells genetically deficient in S1P1 further con-
firmed that S1P1 is required for lymphocytes to egress
from thymus and lymphoid organs and suggested that
agonist-induced S1P1 receptor desensitization (func-
tional antagonism) could account for FTY720-induced
lymphocyte sequestration [19, 30, 31]. Pharmacologi-
cal probes with specificity for S1P1 will be useful
in elucidating the function of this receptor in a variety
of biological settings. Here, we report the discovery of
such a tool, a monoselective S1P1 agonist (AUY954),
which has desirable pharmacokinetic properties and
demonstrates comparable activity to FTY720 in medi-
ating peripheral lymphocyte depletion. Furthermore,
the discovery of AUY954 as a monoselective S1P1 ag-
onist has allowed pharmacological validation of the
S1P1 receptor as a target to prevent allograft rejection
in a stringent rat heart transplantation model.Experimental Procedures
Synthesis of AUY954
Boronic Acid 2
To a solution of 5-methylbenzo[b]thiophene (6.12 g, 41.3 mmol) in
THF (138 ml) at 278C was added LDA (41.3 ml of a 2 M solution,
82.6 mmol), followed by the addition of trimethyl borate (9.26 ml,
82.6 mmol) in neat. The mixture was allowed to warm up to room
temperature overnight. The mixture was cooled to 0C and treated
with 2 N HCl until pH was about 1. After stirring for 1 hr, the mixture
was extracted with EtOAc, and the combined organic solution was
dried (Na2SO4) and concentrated. The crude was washed with hex-
anes to remove trace amount of unreacted 5-methylbenzothio-
phene. The crude product, 5-methylbenzo[b]thiophenylboric acid
(7.01 g, 88%), was used without further purification. 1H NMR
(600 MHz, CD3OD) d 7.78 (s, 1 H), 7.75 (d, J = 8.2 Hz, 1 H), 7.66 (s,
1 H), 7.21 (d, J = 8.0 Hz, 1 H), 2.45 (s, 3 H).
Aniline 4
To a solution of 4-bromo-3-(trifluoromethyl)aniline (91 g, 379 mmol)
in THF (750 ml) were added phenylboric acid (49.23 g, 404 mmol),
Pd(OAc)2 (1.7 g, 7.6 mmol), (dicyclohexylphophino)biphenyl
(5.44 g, 15.2 mmol), and KF (66.09 g, 1138 mmol). The resulting mix-
ture was heated at reflux under nitrogen overnight. The mixture was
filtered through Celite, which was washed with EtOAc. The filtrate
was then concentrated and the residue was purified by column chro-
matography (EtOAc:hexanes = 1:4) to afford 63 g (70%) of aniline 4
as oil. LC-MS m/z 238.1 (M+H+).
Bromide 5
To a solution of aniline 4 (63 g, 266 mmol) in CH3CN (850 ml) at 0
C
was added CuBr2 (62 g, 278 mmol) and then t-BuONO (33 ml,
277 mmol) slowly. The resulting mixture was allowed to warm to
room temperature and continued to stir until the completion of reac-
tion (by TLC). The mixture was diluted with EtOAc (1.5 liter) and
washed with brine (500 ml 3 3). The organic layer was separated,
dried over Na2SO4, and concentrated. The crude was purified by col-
umn chromatography (100% hexanes) to yield 52 g (65%) of bromide
5 as colorless oil. 1H NMR (600 MHz, CDCl3) d 7.88 (d, 1 H), 7.69 (d, 1
H), 7.44–7.38 (m, 3 H), 7.32–7.28 (m, 2 H), 7.21 (d, 1 H); GC-MS m/z
302 (M+2), 300 (M).
Benzothiophene 6
Pd(PPh3)4 (803 mg, 0.70 mmol) was added to a solution of boric acid
2 (7.01 g, 36.5 mmol) and bromide 5 (10.46 g, 34.76 mmol) in toluene
(160 ml) and ethanol (40 ml), followed by addition of a solution of
Na2CO3 (14.74 g, 139 mmol) in water (160 ml). The mixture was
stirred at 80C for 6 hr until the completion of reaction (by GC-MS).
The reaction mixture was cooled to room temperature and the top
organic layer was separated. The aqueous phase was extracted
with 10% EtOAc/hexane. The combined organic solution was dried
over MgSO4 and filtered through Celite, which was washed with
EtOAc. After concentration, the crude product was purified by
recrystalization with hexane (w50 ml) to give 9.34 g (73%) of com-
pound 6 as light brown solid. 1H NMR (600 MHz, CDCl3) d 8.06 (s,
1 H), 7.87 (d, 1 H), 7.74 (d, 1 H), 7.61 (s, 1 H), 7.58 (s, 1 H), 7.45–
7.35 (m, 6 H), 7.20 (d, 1 H), 2.49 (s, 3 H); GC-MS m/z 368 (M).
Benzyl Bromide 7
To a solution of compound 6 (4.88 g, 13.25 mmol) in carbon tetra-
chloride (130 ml) was added N-bromosuccinimide (2.47 g,
13.9 mmol) and 2,20-azobisisobuyronitrile (AIBN, 435 mg, 2.65
mmol). The mixture was stirred at 95C for 10 hr and then cooled
to room temperature. The solution was passed through a pad of sil-
ica gel, which was further rinsed with EtOAc-hexanes (1:9). The
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crude) of compound 7, which was used without further purification.
t-Butyl Ester 8
Sodium hydride (1.27 g, 60% dispersion in mineral oil, 31.7 mmol)
was added to a solution of b-alanine t-butyl ester hydrochloride
(3.46 g, 19.1 mmol) in DMF (20 ml) at 0C. After stirring at room tem-
perature for 10 min, a solution of crude compound 7 (5.7 g,
12.7 mmol) in DMF (25 ml) was added slowly, and the mixture was
stirred at room temperature overnight. The reaction was quenched
with water (45 ml). The mixture was extracted with EtOAc-hexanes
(1:1). The combined organic solution was washed with water, brine,
and dried over Na2SO4. After concentration, the residue was purified
with column chromatography (gradient, 10%–60% EtOAc/hexanes)
to yield 4.20 g (62% over 2 steps) of compound 8 as viscous oil. 1H
NMR (400 MHz, CDCl3) d 8.05 (s, 1 H), 7.90–7.75 (m, 3 H), 7.61 (s, 1 H),
7.45–7.30 (m, 7 H), 5.08 (br s, 2 H), 3.97 (s, 2 H), 2.94 (t, 2 H), 2.54 (t, 2
H), 1.45 (s, 9 H); LC/MS m/z 512.4 (M+H+).
AUY954
To a solution of ester 8 (4.20 g, 8.21 mmol) in methylene chloride
(30 ml) was added trifluoroacetic acid (15 ml), and the mixture was
stirred at room temperature until the completion of reaction (by
LC-MS). The mixture was concentrated, and the resulting solid
was fully dissolved in hot EtOAc (w45 ml) followed by addition of
hexanes (w3 ml). The solution was cooled to room temperature
and solid was formed. After filtration, the solid was redissolved in
a hot mixture of CH3CN (30 ml) and 2 N HCl (15 ml). The solution
was concentrated to dryness to afford 2.7 g (66%) of AUY954 as
HCl salt. 1H NMR (400 MHz, DMSO-d6) d 9.20 (br s, 2 H), 8.20 (s, 2
H), 8.13 (s, 1 H), 8.11 (s, 1 H), 8.04 (s, 1 H), 7.59–7.52 (m, 2 H), 7.50–
7.43 (m, 3 H), 7.40–7.34 (m, 2 H), 4.31 (s, 2 H), 3.15 (t, 2 H), 2.73 (t, 2
H); 19F NMR (400 MHz, DMSO-d6) d -55.48; MS m/z 456.1 (M+H
+).
S1P1 Homology Model and Docking Studies
The S1P1 model was developed by homology modeling in the MOE
program suite 2003.02 (Chemical Computing Group, Montreal, Can-
ada). The template used in homology modeling was the bovine rho-
dopsin crystal structure (PDB code 1F88) [32], and the sequence
alignment between S1P1 and Rhodopsin was taken from the papers
published by A. Parrill et al. [33, 34]. The extracellular b sheet 4 (b4)
that forms the top of the retinal binding site in the rhodopsin crystal
structure was found to block the docking of S1P into the transmem-
brane region. Therefore, residues on the b4 sheet from Val173 to
His195 of rhodopsin were deleted from the homology template, leav-
ing the corresponding residues Met180 to Leu195 on S1P1 as a gap
and modeled without a template.
Docking was performed with GOLD v1.2 (Cambridge Crystallo-
graphic Data Center) [35]. All atom types and charges were assigned
in GOLD. The protein was fixed while the ligands were flexible in the
docking. All parameters were taken from the standard default set-
tings. One-hundred thousand independent genetic algorithm (GA)
runs were performed for each compound. The radius of the search
was set to 15 A˚.
Receptors and Cell Lines
Stable cell lines expressing human S1P receptors were prepared by
transfecting CHO cells with pcDNA3.1 (Invitrogen Corporation) ex-
pression vectors encoding N-terminally myc-tag hS1P1 and S1P3
(cDNAs were a gift from J.P. Hobson [36]), with pRc/CMV encoding
S1P4 [36] and with pcDNA 3.1 Topo V (Invitrogen Corporation) in
which PCR-amplified (sequence verified) mS1P1, S1P2, and S1P5
were cloned. Stable clones were selected in the presence of
0.5 mg/ml G418 (Invitrogen Corporation) and evaluated for high
expression of functional receptors.
GTPg35S-Binding Assay
The cells expressing S1P receptors were harvested in 20 ml cold
10 mM HEPES (pH 7.5), 0.1% fatty-acid-free bovine serum albumin
(BSA), and protease inhibitors cocktail (1/50 complete, Roche Ap-
plied Science), centrifuged at 750 3 g for 10 min at 4C, and resus-
pended in 10 ml 20 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl2,
1 mM EDTA, 0.1% BSA, and protease inhibitors cocktail. The cell
suspension was homogenized on ice with a Polytron homogenizer
at 25,000 rpm, centrifuged at 26,9003 g for 30 min at 4C, and resus-
pended in 20 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 1 mMEDTA, and 0.1% fat-free BSA at 2–3 mg protein/ml. To characterize
the GTPg35S binding, membrane proteins were resuspended at
75 mg/ml in 50 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 20 mg/ml
saponin, and 0.1% fat-free BSA (pH 7.4) mixed with 5 mg/ml with
WGA-coated SPA-bead (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK), 10 mM GDP, and different concentrations
of agonists and incubated for 10–15 min at RT. The GTPg35S-binding
reaction was started by the addition of 200 pM GTPg35S (Amersham,
>1000 Ci/mmol). After 120 min at room temperature, the plates were
centrifuged for 10 min at 2000 rpm and counted with a TopCount
instrument (Packard Instruments).
Analysis of Erk and Akt Activation
hS1P1-CHO cells were plated in 6-well dishes at 300,000 cells per
well in normal medium. Cells were serum starved overnight before
stimulation and then cultivated in fresh serum-free medium. Cells
were stimulated at 37C for 5 min with various dilutions of AUY954
or S1P. Cells were harvested by using CHAPS lysis buffer (50 mM
Tris-HCl [pH 8.0], 125 mM NaCl, 20 mM CHAPS, 2 mM DTT, 1 mM
EDTA, 2 mM NaVO4, 10 mM NaF, 1 mM PMSF, 13 Complete
EDTA-free protease inhibitor cocktail [Roche; 300 ul/well]). Cell
lysates were vortexed for 10 s and spun at 15,000 3 g for 5 min at
4C. Resulting supernatants were then subjected to standard
SDS-PAGE and western blotting analysis. The following primary an-
tibodies were used: monoclonal anti-phospho Erk antibody (Santa
Cruz Biotechnology, catalog number sc-7383), polyclonal anti-
phospho Akt antibody (Cell Signaling catalog number 4051), poly-
clonal anti-Erk antibody (Santa Cruz Biotechnology), and polyclonal
anti-Akt antibody (BD Pharmingen). Anti-mouse IgG HRP-
conjugated and anti-rabbit IgG HRP-conjugated (Promega) were
used as secondary antibodies. ECL Plus Western Blotting Detection
Kit (Amersham) was used for signal detection. The film was exposed
between 3 s to 1 min for optimal resolution of the specific bands.
Peripheral Blood Lymphocyte Depletion Assay
Lewis rats were subjected to a single dose of either vehicle (control)
or AUY954 via oral administration. Sublingual blood for hematolog-
ical monitoring was obtained before AUY954 administration (base-
line) and 6 and 48 hr after drug application.
Rats were anaesthetized with isoflurane 5% v/v (Forene, Abbott,
Baar, CH). Whole blood was sampled from the sublingual vein in
EDTA-coated Eppendorf tubes and subjected to hematology analy-
sis. Absolute and differential leukocyte counts, including lympho-
cyte counts were analyzed with the Technicon H1-E analyzer(Bayer
Diagnostics, Zu¨rich, CH).
Pharmacokinetic Analysis
The whole blood sample from Lewis rats treated with compound
AUY954 was taken sublingually in EDTA tubes and was stored at
280C. One hundred microliters of each blood sample was trans-
ferred to 2.0 ml Eppendorf tube. Fifty microliters of internal standard
solution at a concentration of 0.2 ug/ml was added to each sample.
After mixing with vortex for 10 s, 50 ul of a boric acid/borax buffer
(pH 9.0) and 750 ul of ethyl acetate were added. After vortexing for
10 s, samples were ultrasonicated for 5 min and then rotated for
10 min on Rotator Drive. The two liquid layers were separated by
a short centrifugation step. A 650 ul aliquot of upper organic layer
was transferred into 1.5 ml Eppendorf tube. The organic supernatant
was evaporated to dryness. The residue was dissolved in 35 ul 50%
methanol by ultrasonicating and vortexing for 5 min. Then 35 ul of
0.4% formic acid was added. After a further step of ultrasonicating
and vortexing for 5 min, the residual particles were separated by
centrifugation for 5 min at 16,1003 g at room temperature. Sixty mi-
croliters of each sample was transferred to microvial and stored at
12C prior to analysis. Ten microliters of the above prepared sample
was directly injected onto a Zorbax SB-C18 (0.5 mm 3 75 mm,
3.5 mm) analytical column, and target analyte (AUY954) was eluted
by a gradient method with a mobile phase consisting of 0.2% formic
acid in water (solvent A) and 0.2% formic acid in acetonitrile (solvent
B). The gradient started at 95% A for the first 4 min, changed to 80%
A at 5 min, further changed to 5% A at 14 min and kept constant
to 16 min, and reverted to 95% A at 16.1 min to re-equilibrate the
column for 4 min. The flow rate was 20 ul/min. The retention time
of AUY954 was 11.6 min. The HPLC system was interfaced to
Discovery of a Selective S1P Receptor-1 Agonist
1233a Micromass Micro triple quadrupole mass spectrometer with an
electrospray source. AUY954 was monitored by multiple-reaction
monitoring (MRM). The limit of quantitation (LOQ) of AUY954 was
1 ng/ml, and the linear dynamic range was 1–10,000 ng/ml.
Heterotopic Vascular Heart Transplantation in DA to Lewis Rats
Inbred male DA (RT1a) and Lewis (RT11) rats obtained from Harlan,
Zeist, Netherlands were used as mismatched donors and recipients,
respectively. Donor heart grafts were transplanted onto the recipient
abdominal aorta and inferior vena cava by standard microsurgical
techniques [37]. Either 0.3 mg/kg/day of RAD001 or different doses
(1, 3, or 10 mg/kg/day) of AUY954, in combination with 0.3 mg/kg/
day of RAD001 was given to the recipients by gavage. Treatment
started 3 days before transplantation and lasted for 26 days after
transplantation. Graft survival was monitored daily by palpation for
the ventricular contraction. Hearts possessing a complete cessation
of ventricular motion were considered rejected. At autopsy, heart al-
lografts were harvested for histopathological evaluation. The degree
of acute cardiac rejection was scored with a scale of zero to four: 0,
no rejection; 1, slight; 2, moderate; 3, marked; 4, severe.
Five groups were studied as follows: group 1 (n = 7) received
pyrogen free water as placebo; group 2 (n = 6) received RAD001
(0.3 mg/kg/d); group 3 (n = 5) received AUY954 (1 mg/kg/d) and
RAD001 (0.3 mg/kg/d); group 3 (n = 5) received AUY954 (3 mg/kg/
d) and RAD001 (0.3 mg/kg/d); and group 3 (n = 5) received
AUY954 (10 mg/kg/d) and RAD001 (0.3 mg/kg/d).
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